News and Trends 14 Jan 2020
Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany
The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene […]